These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 29598982)
1. Re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028. Bratt O; Öfverholm A Eur Urol; 2018 Jul; 74(1):e9. PubMed ID: 29598982 [No Abstract] [Full Text] [Related]
2. Reply to Ola Bratt and Anna Öfverholm's Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028. Eklund M; Ström P; Nordström T; Grönberg H Eur Urol; 2018 Jul; 74(1):e10-e11. PubMed ID: 29598984 [No Abstract] [Full Text] [Related]
3. Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46. Vickers A; Nordström T; Assel M; Lilja H; Grönberg H; Eklund M Eur Urol; 2018 Aug; 74(2):e35-e36. PubMed ID: 29731258 [No Abstract] [Full Text] [Related]
4. Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Grönberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol 2018;74:722-8. Eklund M; Ström P; Grönberg H; Nordström T Eur Urol; 2019 Apr; 75(4):e104-e105. PubMed ID: 30514569 [No Abstract] [Full Text] [Related]
5. Re: Henrik Grönberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol 2018;74:722-8. Rud E; Lauritzen P; Baco E Eur Urol; 2019 Apr; 75(4):e103. PubMed ID: 30528223 [No Abstract] [Full Text] [Related]
6. Re: Cathrine Alvær Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Grönberg, Bjørnar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009. Liu W; He Y; Yang B Eur Urol Focus; 2024 Mar; 10(2):244-245. PubMed ID: 38290858 [No Abstract] [Full Text] [Related]
7. Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028. Wang B; Deng H; Cao L Eur Urol; 2019 Nov; 76(5):e125. PubMed ID: 31109815 [No Abstract] [Full Text] [Related]
8. Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Ayubi E; Safiri S Eur Urol; 2017 Dec; 72(6):e157. PubMed ID: 28576506 [No Abstract] [Full Text] [Related]
9. Re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Bosas P; Zaleskis G; Characiejus D Eur Urol; 2022 Oct; 82(4):e113-e114. PubMed ID: 35907665 [No Abstract] [Full Text] [Related]
10. Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819-22. Piva F; Santoni M; Scarpelli M; Briganti A; Montorsi F; Montironi R Eur Urol; 2015 Dec; 68(6):e134-5. PubMed ID: 26215609 [No Abstract] [Full Text] [Related]
11. Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015. Cimadamore A; Lopez-Beltran A; Cheng L; Montironi R Eur Urol; 2023 Mar; 83(3):e84-e86. PubMed ID: 36517350 [No Abstract] [Full Text] [Related]
12. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017. Froehner M; Koch R; Thomas C Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458 [No Abstract] [Full Text] [Related]
13. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues. Trock BJ; Karnes RJ Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503 [No Abstract] [Full Text] [Related]
14. Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009. van den Bergh RCN; Valerio M; Tilki D; Gandaglia G; Eur Urol; 2020 Aug; 78(2):e67-e68. PubMed ID: 32303383 [No Abstract] [Full Text] [Related]
15. Re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022. Lu C; Guan X Eur Urol; 2020 Aug; 78(2):e71-e72. PubMed ID: 32389445 [No Abstract] [Full Text] [Related]
16. Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010. Kim SE; Shin JI; Shoag JE Eur Urol; 2021 Jul; 80(1):e14. PubMed ID: 33941402 [No Abstract] [Full Text] [Related]
17. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007. Wei Y; Ye D; Zhu Y Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186 [No Abstract] [Full Text] [Related]
18. Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate. Cimadamore A; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R Eur Urol; 2021 Sep; 80(3):e81-e82. PubMed ID: 34148712 [No Abstract] [Full Text] [Related]
19. Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041. Orczyk C; Marsden T; Emberton M Eur Urol; 2021 Mar; 79(3):e98-e99. PubMed ID: 33341284 [No Abstract] [Full Text] [Related]
20. Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009. Du J; Liu Y; Yan W Eur Urol; 2020 Aug; 78(2):e64. PubMed ID: 32362499 [No Abstract] [Full Text] [Related] [Next] [New Search]